View Older Stories View More Recent Stories

Apr 8, 2024 04:01PM Kineta (KA) Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Apr 8, 2024 04:01PM Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Mar 21, 2024 04:02PM Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
Mar 12, 2024 08:00AM KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
Feb 29, 2024 08:32AM Kineta (KA) Announces Restructuring and Exploration of Strategic Alternatives
Feb 29, 2024 08:30AM Kineta Announces Restructuring and Exploration of Strategic Alternatives
Feb 22, 2024 08:30AM Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
Feb 14, 2024 08:30AM Kineta to Present at Upcoming Investor Conferences
Feb 7, 2024 08:30AM Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
Jan 17, 2024 08:31AM Kineta (KA) Provides Update on its Ongoing Phase 1/2 VISTA-101 Trial of KVA12123
Jan 17, 2024 08:30AM Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
Jan 4, 2024 08:30AM Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
Dec 13, 2023 08:31AM Kineta (KA) Reports Publication of Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123
Dec 13, 2023 08:30AM Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
Dec 12, 2023 09:24AM Kineta to Present at the Life Sciences Investor Forum December 14th
Nov 28, 2023 08:30AM Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
Nov 9, 2023 08:30AM Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
Nov 6, 2023 08:30AM Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Nov 3, 2023 04:01PM Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 3, 2023 04:00PM Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Oct 17, 2023 08:30AM Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Oct 12, 2023 10:19AM Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023
Oct 9, 2023 12:10PM Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
Oct 5, 2023 04:09PM Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Oct 4, 2023 08:30AM Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
Oct 4, 2023 08:00AM Kineta (KA) Prices 890K Share Offering at $3.37/sh
Oct 4, 2023 08:00AM Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Oct 3, 2023 08:32AM Kineta (KA) Reports Positive KVA12123 Monotherapy Safety and Biomarker Data
Oct 3, 2023 08:30AM Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Sep 28, 2023 09:30AM Kineta Announces Participation at October Investor Conferences
Sep 25, 2023 09:30AM Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
Sep 18, 2023 09:30AM Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
Aug 31, 2023 09:30AM Kineta to Participate in Upcoming Investor Conferences
Aug 11, 2023 04:01PM Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jun 29, 2023 06:31AM Kineta (KA) to Receive $5M Milestone Payment from Merck
Jun 29, 2023 06:30AM Kineta to Receive $5 Million Milestone Payment from Merck
Jun 28, 2023 06:30AM Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
May 24, 2023 06:32AM Kineta (KA) to Join Russell Microcap Index
May 24, 2023 06:30AM Kineta Set to Join Russell Microcap® Index
May 23, 2023 06:30AM Kineta to Present at Jefferies Healthcare Conference
May 11, 2023 05:20PM Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
Apr 24, 2023 04:01PM Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Apr 20, 2023 08:39AM Kineta (KA) Announces $6 Million Registered Direct Offering of Common Stock, Warrants
Apr 20, 2023 08:38AM Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Apr 17, 2023 06:31AM Kineta (KA) Unveils New VISTA Biomarker Data, Provides KVA12123 Phase 1/2 Clinical Trial Update
Apr 17, 2023 06:30AM Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
Apr 12, 2023 06:32AM Kineta (KA) Announces Doses First Patient in Phase 1/2 Clinical Study of KVA12123
Apr 12, 2023 06:30AM Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
Apr 3, 2023 06:30AM Kineta to Present at 22nd Annual Needham Healthcare Conference
Mar 31, 2023 04:03PM Kineta (KA) Reports FY22, Provides Corporate Update
View More Recent Stories View Older Stories